Request Demo
Last update 02 Jul 2026
TQB-3909
Last update 02 Jul 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms TQB-3909, TQB3909 |
Target |
Action inhibitors |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
10
Clinical Trials associated with TQB-3909NCT06245941
A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Moderate- and High-risk Myelofibrosis
NCT07011186
A Phase Ib/II Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of TQB3909 Tablets in Combination With Azacitidine in Subjects With Myeloid Malignancies
NCT06211751
A Phase Ib Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of TQB3909 Tablets Combined With TQB3702 Tablets in Hematologic Malignancy Subjects.
100 Clinical Results associated with TQB-3909
Login to view more data
100 Translational Medicine associated with TQB-3909
Login to view more data
100 Patents (Medical) associated with TQB-3909
Login to view more data
1
Literatures (Medical) associated with TQB-390901 Dec 2025CANCER CHEMOTHERAPY AND PHARMACOLOGY
Prediction of CYP3A4-mediated drug-drug interactions of a novel Bcl-2 inhibitor TQB3909 using physiologically based pharmacokinetic modeling
Article
Author: Yang, Anqi ; Chen, Hui ; Li, Xu ; Wang, Xin ; Yu, Ding ; Zhao, Wei ; Zhu, Shixing ; Wang, Xunqiang
100 Deals associated with TQB-3909
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Lymphocytic Leukemia | Phase 3 | China | 21 Apr 2026 | |
| Small Lymphocytic Lymphoma | Phase 3 | China | 21 Apr 2026 | |
| Post-essential thrombocythemia myelofibrosis | Phase 2 | China | 13 May 2024 | |
| Post-polycythemia vera myelofibrosis | Phase 2 | China | 13 May 2024 | |
| Primary Myelofibrosis | Phase 2 | China | 13 May 2024 | |
| Acute Myeloid Leukemia | Phase 2 | China | 25 Apr 2024 | |
| Myelodysplastic Syndromes | Phase 2 | China | 25 Apr 2024 | |
| Myeloid Tumor | Phase 2 | China | 17 Apr 2024 | |
| Chronic lymphocytic leukaemia refractory | Phase 2 | China | 11 Oct 2023 | |
| Mantle cell lymphoma recurrent | Phase 2 | China | 20 Sep 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 16 | TQB3909+Ruxolitinib | sclgeeuwkh(oevnjvcpgy) = fwkuodsnas vopsmkwqov (kamnqohwpw ) | Positive | 06 Dec 2025 | ||
cztdrahdwb(eokpldmcpm) = irtwliembb qyxcswalnf (mugomdyqyh ) View more | |||||||
Phase 1/2 | 56 | TQB3909+AZA | dvagcjbouj(wlgwxwntqd) = xnjfsunhhe lmvwfnocsg (zsvluhvqbr ) View more | Positive | 06 Dec 2025 | ||
TQB3909+AZA (400mg) | vnuknaewqg(lwvlsczjlb) = izhxjhblty jydbpurmzz (hvnpuvsaxt ) View more | ||||||
Phase 1/2 | Small Lymphocytic Lymphoma Second line | 27 | fszvarnnpk(lcflgsymrz) = jjltahyrtj crztxfjujn (qevjyyihda ) View more | Positive | 09 Dec 2024 | ||
Phase 1 | 69 | (CLL/SLL) | duyiqirtod(kkfnaslnsm) = None scahouongv (mujgzrpgjq ) View more | Positive | 13 Sep 2024 | ||
(B-NHL) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free